Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Keep containers tightly sealed and protected from light and moisture to help maintain peptide stability
Reduced efficacy concerns GLP-1 receptor agonists are designed to work at specific doses to achieve optimal receptor activation (saturation) and to provide full therapeutic effect
If you are taking blood-thinning medications (anticoagulants), please consult with your healthcare practitioner before beginning use of ALCAR
The SURMOUNT trial program provides extensive data on what tirzepatide achieves without any additional weight loss medication: 5 mg dose: 15.0% average weight loss at 72 weeks 10 mg dose: 19.5% average weight loss at 72 weeks 15 mg dose: 20.9% average weight loss at 72 weeks At 15 mg, 56.1% of participants lost at least 20% of body weight At 15 mg, 38.7% of participants lost at least 25% of body weight These numbers are remarkable
/assets/images/provider/photos/2775905.jpeg)
